Medicinal cannabis company wins Deloitte’s Tech Fast 50

Australian medicinal cannabis company, Montu, has received first place in Deloitte’s Technology Fast 50 awards, which recognise the most successful and fastest growing Australian technology companies based on revenue growth rates over the past three years.

Montu Managing Director Christopher Strauch founded the company with the mission to provide patients with an alternative to conventional medication and help millions of people worldwide live better lives.

Mr Strauch says the company is proud to provide Australians with a “powerful alternative to traditional medications” and to “create a new standard in patient care”.

“Our ongoing growth is a result of our patient-centric approach and streamlined process, which gives patients access to a natural plant-based alternative to manage their chronic conditions in a fast and affordable way,” he said.

“Our key focus is to provide the best care and outcomes for our patients so they can experience the many benefits of medicinal cannabis when used and administered correctly.”

Conducting more than 50,000 patient consultations every year, Montu is making medicinal cannabis accessible and affordable to Australians with chronic medical conditions.

Consultations are conducted via the integrated telehealth platform, alternaleaf, with practitioners including registered nurses and qualified doctors.

The company’s clinical team provides patients with individualised care and alternative treatments for a range of chronic conditions, including chronic pain, anxiety, insomnia, and depression, to name a few.

Dr Parul Agarwal has been a doctor for the past 18 years and became an authorised medicinal cannabis prescriber two years ago after seeing a significant improvement in her patients with chronic pain.

“I started to prescribe medicinal cannabis as my patients were looking for natural remedies, especially cancer patients who needed help with chronic pain,” she said.

“I found that it worked beautifully for chronic pain, anxiety, depression, PTSD, ADHD and insomnia. I have seen how it has given my patients a better quality of life. I believe this is the beginning of how we perceive alternative medicine.”

For more information about Montu, visit: montu.com.au.

Must Read

New regional roadmaps for prioritising antimicrobial resistance

0
A new publication by the International Pharmaceutical Federation (FIP) identifies priority actions pharmacists should take to minimise antimicrobial resistance (AMR). The publication presents six...